沙利度胺治疗特发性骨髓纤维化的研究进展

Advances in Thalidomide Therapy for Idiopathic Myelofibrosis

特发性骨髓纤维化是慢性骨髓增殖性疾病的一种,预后较差。造血干细胞移植能改善该病预后,但只适用于少数患者。目前多采用姑息性治疗措施,如雄激素、羟基脲等,疗效并不满意。沙利度胺兼具抗血管新生和抑制细胞因子的特性,在特发性骨髓纤维化的治疗中有一定疗效。

Idiopathic myelofibros is a Philadelphia-negative chronic myeloproliferative disorder. Potentially curative therapies, such as stem-cell transplantation, are reserved only for a minority of patients. Currently palliative therapies such as androgen and hydroxycarbamide are commonly used but with poor results. Thalidomide has anti-angiogenic effect and also can inhibit cytokines, and therefore plays a certain role in the treatment of a subset of idiopathic myelofibros.